Coherus Oncology, Inc.
CHRS
$1.20
$0.065.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | 32.25% | 25.75% | -230.49% | -- |
| Total Depreciation and Amortization | -- | -15.77% | -13.26% | -37.64% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -82.80% | -97.09% | -127.36% | -- |
| Change in Net Operating Assets | -- | -318.08% | -70.04% | 84.74% | -- |
| Cash from Operations | -- | -124.14% | -168.92% | 25.28% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 275.31% | -423.62% | -15,241.22% | -- |
| Cash from Investing | -- | 275.31% | -423.62% | -15,241.22% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 3,243.98% | -- | -- |
| Repurchase of Common Stock | -- | 57.58% | 100.00% | 70.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 131.25% | -- |
| Cash from Financing | -- | 20,399.24% | 3,398.27% | 101.20% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 160.49% | -151.15% | -83.94% | -- |